|Chemical and physical data|
|Molar mass||149.0 kg/mol g·mol−1|
Enfortumab vedotin (ASG-22ME) is an antibody-drug conjugate designed for the treatment of cancer expressing Nectin-4. Enfortumab refers to the monoclonal antibody part, and vedotin refers to the payload drug (MMAE) and the linker.
The fully humanized antibody was created by scientists at Agensys (part of Astellas) using Xenomice from Amgen; the linker technology holding the antibody and the toxin together was provided by and licensed from Seattle Genetics.
Results of a phase I clinical trial were reported in 2016.
|This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.|